Showing results (481-490 of 2,132) with videos related to
Sort By:
Pageof 214
Biopharmaceutics & Drug Disposition|March 21, 2014
Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addictionFei Liu, Xiaomei Zhuang, Cuiping Yang, et al.Biopharmaceutics & Drug Disposition|December 28, 2016
Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between α-tocopherol and ezetimibeShunsuke Nashimoto, Yuki Sato, Yoh Takekuma, et al.Biopharmaceutics & Drug Disposition|February 3, 2017
A comparative evaluation of models to predict human intestinal metabolism from nonclinical dataEstelle Yau, Carl Petersson, Hugues Dolgos, et al.Biopharmaceutics & Drug Disposition|October 21, 2016
Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysisShin-Ichi Inaba, Maki Goto, Kaoru Tanaka-Takanaka, et al.Biopharmaceutics & Drug Disposition|March 12, 2014
Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronideTakaaki Kodawara, Satohiro Masuda, Yoshitaka Yano, et al.Biopharmaceutics & Drug Disposition|October 4, 2016
Atazanavir increases the plasma concentrations of 1200 mg raltegravir doseRajesh Krishna, Lilly East, Patrick Larson, et al.Biopharmaceutics & Drug Disposition|April 5, 2017
Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalersKonstantina Soulele, Panos Macheras, Vangelis KaralisBiopharmaceutics & Drug Disposition|October 19, 2018
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case exampleYuan Chen, Rui Zhu, Fang Ma, et al.Biopharmaceutics & Drug Disposition|December 22, 2007
Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotypeH J M van Kan, L H van den Berg, G J Groeneveld, et al.Biopharmaceutics & Drug Disposition|May 7, 2014
Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescentsTrevor N Johnson, Diansong Zhou, Khanh H BuiPageof 214